A J Kazimi bought $1,318 of CPIX
Chairman and CEO at CUMBERLAND PHARMACEUTICALS INC. 769 shares at an average of $1.71, traded Dec 2, 2024, filed Dec 30, 2024.
Score components
- +25RoleCEO
- 0Trade size$1k at market
- -5Relative to holdingsUnder 1% of holdings (0.0%)
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -1510b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-24-052606, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2024 | POpen-market purchase Common Stock10b5-1 | +70 | $1.33 | $93 | 5,701,597 | Dec 30, 2024 |
| Dec 3, 2024 | POpen-market purchase Common Stock10b5-1 | +70 | $1.26 | $88 | 5,701,667 | Dec 30, 2024 |
| Dec 4, 2024 | POpen-market purchase Common Stock10b5-1 | +70 | $1.22 | $85 | 5,701,737 | Dec 30, 2024 |
| Dec 5, 2024 | POpen-market purchase Common Stock10b5-1 | +65 | $1.20 | $78 | 5,701,802 | Dec 30, 2024 |
| Dec 6, 2024 | POpen-market purchase Common Stock10b5-1 | +70 | $1.20 | $84 | 5,701,872 | Dec 30, 2024 |
| Dec 9, 2024 | POpen-market purchase Common Stock10b5-1 | +70 | $1.25 | $88 | 5,701,942 | Dec 30, 2024 |
| Dec 10, 2024 | POpen-market purchase Common Stock10b5-1 | +32 | $2.48 | $79 | 5,701,974 | Dec 30, 2024 |
| Dec 11, 2024 | POpen-market purchase Common Stock10b5-1 | +32 | $2.29 | $73 | 5,702,006 | Dec 30, 2024 |
| Dec 12, 2024 | POpen-market purchase Common Stock10b5-1 | +32 | $2.19 | $70 | 5,702,038 | Dec 30, 2024 |
| Dec 13, 2024 | POpen-market purchase Common Stock10b5-1 | +32 | $2.33 | $75 | 5,702,070 | Dec 30, 2024 |
| Dec 16, 2024 | POpen-market purchase Common Stock10b5-1 | +49 | $2.21 | $108 | 5,702,119 | Dec 30, 2024 |
| Dec 17, 2024 | POpen-market purchase Common Stock10b5-1 | +49 | $2.12 | $104 | 5,702,168 | Dec 30, 2024 |
| Dec 18, 2024 | POpen-market purchase Common Stock10b5-1 | +49 | $2.19 | $107 | 5,702,217 | Dec 30, 2024 |
| Dec 19, 2024 | POpen-market purchase Common Stock10b5-1 | +40 | $2.33 | $93 | 5,702,257 | Dec 30, 2024 |
| Dec 20, 2024 | POpen-market purchase Common Stock10b5-1 | +39 | $2.35 | $92 | 5,702,296 | Dec 30, 2024 |
Related signals
Other insiders at CUMBERLAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $858 168 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $429 84 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $858 168 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,824 945 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,635 1,035 shares | +0% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $833 186 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $833 186 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $417 93 shares | +0% | |
| 14Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,548 875 shares | +0% | |
| 24Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $881 168 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.